



ASX Announcement

27 October 2016

BINDING LOI FOR COMMERCIALISATION OF CRESO'S FIRST HUMAN NUTRACEUTICAL PRODUCT IN THE SWISS MARKET

Highlights:

- **Swiss Pharma Company, Streuli Pharma, enters into Cannabis and Hemp derived therapeutic field**
- **Binding Letter of Intent (LOI) with Streuli Pharma for the commercialisation of Cannabis and Hemp based nutraceutical products based on INNutri Soft Gums™ technology in the Swiss market**
- **INNutri Soft Gums™ use an innovative and proprietary delivery technology allowing for an optimal bioavailability and absorption of cannabis and hemp derived therapeutics**
- **Nutraceuticals market represents a multi-billion dollar opportunity - global market is expected to reach US\$205 billion by 2017**
- **Creso is pursuing other commercialisation partnerships for the rest of Europe and globally**

Creso Pharma Limited (ASX: CPH, the "Company") is pleased to announce that it has signed a binding letter of intent (LOI) with Swiss pharmaceutical firm, Streuli Pharma, for the commercialisation of its first human nutraceutical product, INNutri Soft Gums™ in the Swiss market. Streuli Pharma currently manufacture over 150 million tablets and capsules per annum and we are extremely pleased that Creso Pharma's INNutri Soft Gums™ will be added to Streuli Pharma's distribution network.

Creso's INNutri Soft Gums™ use an innovative and proprietary delivery technology for optimum delivery of cannabis and hemp derived therapeutic products. The cannabis is delivered through buccal absorption and the soft-gums have several advantages over existing health supplement products. They are easier to ingest than regular gelatin-based products as they are starch-based and are around 60% cheaper than gelatin capsules. INNutri Soft Gums™ are also vegan, halal and kosher as well as gluten and lactose free. The gums are ideal for pediatric and geriatric use.



INNutri Soft Gums™ pictured above

The nutraceuticals market represents a multi-billion dollar opportunity for Creso Pharma. The global market is expected to reach US\$205 billion by 2017 from a market size of US\$142 billion in 2011. Meanwhile, the nutraceutical ingredient market is forecast to reach US\$34 billion by 2018. The Swiss nutraceuticals ingredient market is estimated to be worth US\$400 million by 2018.

Creso also intends to pursue other commercialisation partnerships for the sale of the INNutri Soft Gums™ across other areas of Europe including the Benelux countries, Italy and Spain, as well as globally – Canada, Latin America and Gulf States.

“We are very pleased to be commercialising our first human nutraceutical product with Streuli Pharma. The nutraceutical treatment market represents a significant opportunity for Creso and we expect demand for our human health products to be strong given the growth in the European market,” said Creso Pharma CEO and Co-Founder, Dr. Miri Halperin Wernli.

“Whilst we are initially focusing on the Swiss market, we will be working on developing additional partnership agreements for our innovative cannabis and hemp derived therapeutic products for the rest of Europe and globally.”

About Streuli Pharma

Streuli Pharma, Swiss based pharmaceutical company was founded in 1867.

It has 150 years of tradition connected with innovation. Streuli Pharma is active in R&D, Production, Quality Assurance, Manufacturing and Commercialization. Streuli Pharma produces approximately 150 million tablets and capsules, 4 million ampoules and various other galenic forms such as ointments, gels or suppositories annually. The Streuli products are manufactured, inspected and distributed in Switzerland.

---END---



ABN: 89 609 406 911

Investor Enquiries:

Gabriella Hold
M: 0411 364 382
E: gabriella.hold@mcpartners.com.au

Media Enquiries:

Harrison Polites
M: 0409 623 618
E: harrison.polites@mcpartners.com.au

Corporate Queries:

EverBlu Capital
Level 39, Aurora Place
88 Phillip Street,
Sydney, NSW 2000
E: info@everblucapital.com
P: +61 2 8249 4371

About Creso Pharma

Creso Pharma will lead the field of cannabis derived therapeutic grade nutraceutical products for human and animal health. Leveraging science and research and focusing on unique and innovative delivery mechanisms, Creso Pharma is developing cannabis and hemp derived therapeutic products, manufactured to the highest pharmaceutical GMP standard and delivered to the highest quality levels across the supply chain. Creso is the leader in cannabidiol (CBD) innovation, bringing vast therapeutic choices and opportunities to human and animal health medicine.